Abstract
Inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, is characterized by extensive inflammation due to dysregulation of the innate and adaptive immune system whose exact etiology is not yet completely understood. Currently there is no cure for IBD, thus the search for new molecules capable of controlling IBD and their delivery to the site of inflammation are the goal of many researchers. The aim of this work was to evaluate the anti-inflammatory effect of the administration of milks fermented by a Lactococcus (L.) lactis strain producing 15-lipoxygenase-1 (15-LOX-1) using a trinitrobenzenesulfonic acid-induced IBD mouse model. The results obtained demonstrated that 15-LOX-1 producing L. lactis was effective in the prevention of the intestinal damage associated to inflammatory bowel disease in a murine model. The work also confirmed previous studies showing that fermented milk is an effective form of administration of recombinant lactic acid bacteria expressing beneficial molecules.
Keywords: Colitis, fermented milk, inflammation, lactic acid bacteria, Lactococcus lactis lipoxygenase.
Current Pharmaceutical Biotechnology
Title:Milk Fermented with a 15-Lipoxygenase-1-Producing Lactococcus Lactis Alleviates Symptoms of colitis in a Murine Model
Volume: 16 Issue: 5
Author(s): Tessalia D.L. Saraiva, Katia Morais, Vanessa B. Pereira, Marcela de Azevedo, Clarissa S. Rocha, Camila C. Prosperi, Ana C. Gomes-Santos, Luis Bermudez-Humaran, Ana M.C. Faria, Herve M. Blottiere, Philippe Langella, Anderson Miyoshi, Alejandra de Moreno de LeBlanc, Jean G. LeBlanc and Vasco Azevedo
Affiliation:
Keywords: Colitis, fermented milk, inflammation, lactic acid bacteria, Lactococcus lactis lipoxygenase.
Abstract: Inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, is characterized by extensive inflammation due to dysregulation of the innate and adaptive immune system whose exact etiology is not yet completely understood. Currently there is no cure for IBD, thus the search for new molecules capable of controlling IBD and their delivery to the site of inflammation are the goal of many researchers. The aim of this work was to evaluate the anti-inflammatory effect of the administration of milks fermented by a Lactococcus (L.) lactis strain producing 15-lipoxygenase-1 (15-LOX-1) using a trinitrobenzenesulfonic acid-induced IBD mouse model. The results obtained demonstrated that 15-LOX-1 producing L. lactis was effective in the prevention of the intestinal damage associated to inflammatory bowel disease in a murine model. The work also confirmed previous studies showing that fermented milk is an effective form of administration of recombinant lactic acid bacteria expressing beneficial molecules.
Export Options
About this article
Cite this article as:
Saraiva D.L. Tessalia, Morais Katia, Pereira B. Vanessa, Azevedo de Marcela, Rocha S. Clarissa, Prosperi C. Camila, Gomes-Santos C. Ana, Bermudez-Humaran Luis, Faria M.C. Ana, Blottiere M. Herve, Langella Philippe, Miyoshi Anderson, LeBlanc de Moreno de Alejandra, LeBlanc G. Jean and Azevedo Vasco, Milk Fermented with a 15-Lipoxygenase-1-Producing Lactococcus Lactis Alleviates Symptoms of colitis in a Murine Model, Current Pharmaceutical Biotechnology 2015; 16 (5) . https://dx.doi.org/10.2174/1389201015666141113123502
DOI https://dx.doi.org/10.2174/1389201015666141113123502 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Mechanistic Study on Altered Pharmacokinetics of Irinotecan by St. Johns Wort
Current Drug Metabolism Lysophospholipids: Synthesis and Biological Aspects
Current Organic Chemistry Curcumin: A Boon to Colonic Diseases
Current Drug Targets Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer
Current Cancer Drug Targets Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology Synthesis and Cytotoxic Evaluation for Some New Dihydropyrimidinone Derivatives for Anticancer Activity
Letters in Drug Design & Discovery Cyclopentenyl Cytosine (CPEC): An Overview of its in vitro and in vivo Activity
Current Cancer Drug Targets Circulatory Estrogen Level Protects Against Breast Cancer in Obese Women
Recent Patents on Anti-Cancer Drug Discovery Diabetes Case Identification Methods Applied to Electronic Medical Record Systems: Their Use in HIV-Infected Patients
Current HIV Research Nanoparticle Based Delivery of Protease Inhibitors to Cancer Cells
Current Medicinal Chemistry Apoptotic Potency of Angiostatic Compounds in the Treatment of Cancer
Current Pharmaceutical Biotechnology Viral Vectors for Gene-Directed Enzyme Prodrug Therapy
Current Gene Therapy The Role of JNK Signalling in Responses to Oxidative DNA Damage
Current Drug Targets Nano-Delivery in Pediatric Tumors: Looking Back, Moving Forward
Anti-Cancer Agents in Medicinal Chemistry Curcumin and Curcumin-like Molecules: From Spice to Drugs
Current Medicinal Chemistry AMPK Function in Aging Process
Current Drug Targets Chemoprevention of Breast Cancer by Dietary Compounds
Anti-Cancer Agents in Medicinal Chemistry Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy
Current Cancer Drug Targets Aliphatic and Aromatic Oxidations, Epoxidation and S-Oxidation of Prodrugs that Yield Active Drug Metabolites
Current Medicinal Chemistry Research Toward Potassium Channels on Tumor Progression
Current Topics in Medicinal Chemistry